Identification and significance of mobilized endothelial progenitor cells in tumor neovascularization of renal cell carcinoma

Tumor Biology

Volumn 35, Issue 9, 2014, Pages 9331-9341

  Yu, Peng ^a   Ge, Yu Zheng ^a   Zhao, Yan ^a   Wu, Jian Ping ^a   Wu, Ran ^a   Zhou, Liu Hua ^a   Jia, Rui Peng ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Angiogenic factor; Angiogenic factor receptor; Endothelial progenitor cells; Neovascularization; Renal cell carcinoma

Indexed keywords

CD31 ANTIGEN; CD34 ANTIGEN; CHEMOKINE RECEPTOR CXCR4; MESSENGER RNA; STROMAL CELL DERIVED FACTOR 1; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2; CXCR4 PROTEIN, HUMAN; VASCULOTROPIN A;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CANCER MODEL; CANCER TISSUE; CAPILLARY DENSITY; CELLULAR DISTRIBUTION; CONTROLLED STUDY; ENDOTHELIAL PROGENITOR CELL; HISTOPATHOLOGY; HUMAN; HUMAN CELL; KIDNEY CARCINOMA; KIDNEY PARENCHYMA; MALE; MOUSE; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; STEM CELL MOBILIZATION; TISSUE LEVEL; TUMOR VASCULARIZATION; ANIMAL; BAGG ALBINO MOUSE; BLOOD; CONFOCAL MICROSCOPY; GENE EXPRESSION REGULATION; GENETICS; IMMUNOHISTOCHEMISTRY; KIDNEY; LIVER TUMOR; METABOLISM; NUDE MOUSE; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL LINE; VASCULARIZATION; XENOGRAFT;

ANIMALS; ANTIGENS, CD31; ANTIGENS, CD34; CARCINOMA, RENAL CELL; CELL LINE, TUMOR; CHEMOKINE CXCL12; ENDOTHELIAL PROGENITOR CELLS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; KIDNEY; LIVER NEOPLASMS; MALE; MICE, INBRED BALB C; MICE, NUDE; MICROSCOPY, CONFOCAL; NEOVASCULARIZATION, PATHOLOGIC; RECEPTORS, CXCR4; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANSPLANTATION, HETEROLOGOUS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 84919838556     PISSN: 10104283     EISSN: None     Source Type: Journal    
DOI: 10.1007/s13277-014-2205-5     Document Type: Article

References (47)

1. Ljungberg B, Hanbury DC, Kuczyk MA, Merseburger AS, Mulders PF, Patard JJ, et al. Renal cell carcinoma guideline. Eur Urol. 2007;51(6):1502–10.
2. MacLennan GT, Bostwick DG. Microvessel density in renal cell carcinoma: lack of prognostic significance. Urology. 1995;46(1):27–30.
3. Yoshino S, Kato M, Okada K. Evaluation of the prognostic significance of microvessel count and tumor size in renal cell carcinoma. Int J Urol. 1998;5(2):119–23.
4. Asahara T, Murohara T, Sullivan A, Silver M, van der Zee R, Li T, et al. Isolation of putative progenitor endothelial cells for angiogenesis. Science. 1997;275(5302):964–7.
5. Davidoff AM, Ng CY, Brown P, Leary MA, Spurbeck WW, Zhou J, et al. Bone marrow-derived cells contribute to tumor neovasculature and, when modified to express an angiogenesis inhibitor, can restrict tumor growth in mice. Clin Cancer Res. 2001;7(9):2870–9.
6. Caprioli A, Minko K, Drevon C, Eichmann A, Dieterlen-Lievre F, Jaffredo T. Hemangioblast commitment in the avian allantois: cellular and molecular aspects. Dev Biol. 2001;238(1):64–78.
7. Hristov M, Erl W, Weber PC. Endothelial progenitor cells: mobilization, differentiation, and homing. Arterioscler Thromb Vasc Biol. 2003;23(7):1185–9.
8. Peichev M, Naiyer AJ, Pereira D, Zhu Z, Lane WJ, Williams M, et al. Expression of VEGFR-2 and AC133 by circulating human CD34(+) cells identifies a population of functional endothelial precursors. Blood. 2000;95(3):952–8.
9. Timmermans F, Van Hauwermeiren F, De Smedt M, Raedt R, Plasschaert F, De Buyzere ML, et al. Endothelial outgrowth cells are not derived from CD133+ cells or CD45+ hematopoietic precursors. Arterioscler Thromb Vasc Biol. 2007;27(7):1572–9.
10. Rafii S. Circulating endothelial precursors: mystery, reality, and promise. J Clin Invest. 2000;105(1):17–9.
11. Hilbe W, Dirnhofer S, Oberwasserlechner F, Schmid T, Gunsilius E, Hilbe G, et al. CD133 positive endothelial progenitor cells contribute to the tumour vasculature in non-small cell lung cancer. J Clin Pathol. 2004;57(9):965–9.
12. Dome B, Timar J, Dobos J, Meszaros L, Raso E, Paku S, et al. Identification and clinical significance of circulating endothelial progenitor cells in human non-small cell lung cancer. Cancer Res. 2006;66(14):7341–7.
13. Shirakawa K, Furuhata S, Watanabe I, Hayase H, Shimizu A, Ikarashi Y, et al. Induction of vasculogenesis in breast cancer models. Br J Cancer. 2002;87(12):1454–61.
14. Arbab AS, Pandit SD, Anderson SA, Yocum GT, Bur M, Frenkel V, et al. Magnetic resonance imaging and confocal microscopy studies of magnetically labeled endothelial progenitor cells trafficking to sites of tumor angiogenesis. Stem Cells. 2006;24(3):671–8.
15. Gao D, Nolan DJ, Mellick AS, Bambino K, McDonnell K, Mittal V. Endothelial progenitor cells control the angiogenic switch in mouse lung metastasis. Science. 2008;319(5860):195–8.
16. Yu D, Sun X, Qiu Y, Zhou J, Wu Y, Zhuang L, et al. Identification and clinical significance of mobilized endothelial progenitor cells in tumor vasculogenesis of hepatocellular carcinoma. Clin Cancer Res. 2007;13(13):3814–24.
17. Bhatt RS, Zurita AJ, O’Neill A, Norden-Zfoni A, Zhang L, Wu HK, et al. Increased mobilisation of circulating endothelial progenitors in von Hippel-Lindau disease and renal cell carcinoma. Br J Cancer. 2011;105(1):112–7.
18. Farace F, Gross-Goupil M, Tournay E, Taylor M, Vimond N, Jacques N, et al. Levels of circulating CD45(dim)CD34(+)VEGFR2(+) progenitor cells correlate with outcome in metastatic renal cell carcinoma patients treated with tyrosine kinase inhibitors. Br J Cancer. 2011;104(7):1144–50.
19. Liu H, Wu R, Jia RP, Zhong B, Zhu JG, Yu P, et al. Ischemic preconditioning increases endothelial progenitor cell number to attenuate partial nephrectomy-induced ischemia/reperfusion injury. PLoS One. 2013;8(1):e55389.
20. De Palma M, Venneri MA, Roca C, Naldini L. Targeting exogenous genes to tumor angiogenesis by transplantation of genetically modified hematopoietic stem cells. Nat Med. 2003;9(6):789–95.
21. Beaudry P, Force J, Naumov GN, Wang A, Baker CH, Ryan A, et al. Differential effects of vascular endothelial growth factor receptor-2 inhibitor ZD6474 on circulating endothelial progenitors and mature circulating endothelial cells: implications for use as a surrogate marker of antiangiogenic activity. Clin Cancer Res. 2005;11(9):3514–22.
22. Wang L, Chen W, Gao L, Yang Q, Liu B, Wu Z, et al. High expression of CXCR4, CXCR7 and SDF-1 predicts poor survival in renal cell carcinoma. World J Surg. 2012;10:212.
23. Patard JJ, Rioux-Leclercq N, Masson D, Zerrouki S, Jouan F, Collet N, et al. Absence of VHL gene alteration and high VEGF expression are associated with tumour aggressiveness and poor survival of renal-cell carcinoma. Br J Cancer. 2009;101(8):1417–24.
24. Zhao FL, Guo W. Expression of stromal derived factor-1 (SDF-1) and chemokine receptor (CXCR4) in bone metastasis of renal carcinoma. Mol Biol Rep. 2011;38(2):1039–45.
25. Zhao Y, Yu P, Wu R, Ge YZ, Wu JP, Zhu JG, et al. Renal cell carcinoma-adjacent tissues enhance mobilization and recruitment of endothelial progenitor cells to promote the invasion of the neoplasm. Biomed Pharmacother. 2013;67(7):643–9.
26. Hattori K, Dias S, Heissig B, Hackett NR, Lyden D, Tateno M, et al. Vascular endothelial growth factor and angiopoietin-1 stimulate postnatal hematopoiesis by recruitment of vasculogenic and hematopoietic stem cells. J Exp Med. 2001;193(9):1005–14.
27. Petit I, Jin D, Rafii S. The SDF-1-CXCR4 signaling pathway: a molecular hub modulating neo-angiogenesis. Trends Immunol. 2007;28(7):299–307.
28. Yang B, Gu W, Peng B, Xu Y, Liu M, Che J, et al. High level of circulating endothelial progenitor cells positively correlates with serum vascular endothelial growth factor in patients with renal cell carcinoma. J Urol. 2012;188(6):2055–61.
29. Hagensen MK, Raarup MK, Mortensen MB, Thim T, Nyengaard JR, Falk E, et al. Circulating endothelial progenitor cells do not contribute to regeneration of endothelium after murine arterial injury. Cardiovasc Res. 2012;93(2):223–31.
30. Wickersheim A, Kerber M, de Miguel LS, Plate KH, Machein MR, et al. Endothelial progenitor cells do not contribute to tumor endothelium in primary and metastatic tumors. Int J Cancer. 2009;125(8):1771–7.
31. Ho JW, Pang RW, Lau C, Sun CK, Yu WC, Fan ST, et al. Significance of circulating endothelial progenitor cells in hepatocellular carcinoma. Hepatology. 2006;44(4):836–43.
32. Fürstenberger G, von Moos R, Lucas R, Thurlimann B, Senn HJ, Hamacher J, et al. Circulating endothelial cells and angiogenic serum factors during neoadjuvant chemotherapy of primary breast cancer. Br J Cancer. 2006;94(4):524–31.
33. Richter-Ehrenstein C, Rentzsch J, Runkel S, Schneider A, Schonfelder G. Endothelial progenitor cells in breast cancer patients. Breast Cancer Res Treat. 2007;106(3):343–9.
34. Poon RT, Lau CP, Cheung ST, Yu WC, Fan ST. Quantitative correlation of serum levels and tumor expression of vascular endothelial growth factor in patients with hepatocellular carcinoma. Cancer Res. 2003;63(12):3121–6.
35. Moccia F, Dragoni S, Poletto V, Rosti V, Tanzi F, Ganini C, et al. Orai1 and transient receptor potential channels as novel molecular targets to impair tumor neovascularization in renal cell carcinoma and other malignancies. Anti Cancer Agents Med Chem. 2014;14(2):296–312.
36. Kollet O, Shivtiel S, Chen YQ, Suriawinata J, Thung SN, Dabeva MD, et al. HGF, SDF-1, and MMP-9 are involved in stress-induced human CD34+ stem cell recruitment to the liver. J Clin Invest. 2003;112:160–9.
37. Heissig B, Hattori K, Dias S, Friedrich M, Ferris B, Hackett NR, et al. Recruitment of stem and progenitor cells from the bone marrow niche requires MMP-9 mediated release of kit-ligand. Cell. 2002;109:625–37.
38. Khakoo AY, Finkel T. Endothelial progenitor cells. Annu Rev Med. 2005;56:79–101.
39. Yamaguchi J, Kusano KF, Masuo O, Kawamoto A, Silver M, Murasawa S, et al. Stromal cell-derived factor-1 effects on ex vivo expanded endothelial progenitor cell recruitment for ischemic neovascularization. Circulation. 2003;107(9):1322–8.
40. Ceradini DJ, Kulkarni AR, Callaghan MJ, Tepper OM, Bastidas N, Kleinman ME, et al. Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1. Nat Med. 2004;10(8):858–64.
41. Naik RP, Jin D, Chuang E, Gold EG, Tousimis EA, Moore AL, et al. Circulating endothelial progenitor cells correlate to stage in patients with invasive breast cancer. Breast Cancer Res Treat. 2008;107(1):133–8.
42. Taylor M, Rössler J, Geoerger B, Laplanche A, Hartmann O, Vassal G, et al. High levels of circulating VEGFR2+ bone marrow-derived progenitor cells correlate with metastatic disease in patients with pediatric solid malignancies. Clin Cancer Res. 2009;15(14):4561–71.
43. Deli G, Jin CH, Mu R, Yang S, Liang Y, Chen D, et al. Immunohistochemical assessment of angiogenesis in hepatocellular carcinoma and surrounding cirrhotic liver tissues. World J Gastroenterol. 2005;11(7):960–3.
44. Urbich C, Aicher A, Heeschen C, Dernbach E, Hofmann WK, Zeiher AM, et al. Soluble factors released by endothelial progenitor cells promote migration of endothelial cells and cardiac resident progenitor cells. J Mol Cell Cardiol. 2005;39(5):733–42.
45. Abe-Yoshio Y, Abe K, Miyazaki M, Furusu A, Nishino T, Harada T, et al. Involvement of bone marrow-derived endothelial progenitor cells in glomerular capillary repair in habu snake venom-induced glomerulonephritis. Virchows Arch. 2008;453(1):97–106.
46. Yoshiji H, Harris SR, Thorgeirsson UP. Vascular endothelial growth factor is essential for initial but not continued in vivo growth of human breast carcinoma cells. Cancer Res. 1997;57(18):3924–8.
47. Zhu H, Shao Q, Sun X, Deng Z, Yuan X, Yu D, et al. The mobilization, recruitment and contribution of bone marrow-derived endothelial progenitor cells to the tumor neovascularization occur at an early stage and throughout the entire process of hepatocellular carcinoma growth. Oncol Rep. 2012;28(4):24.